SCHEMBL6890425

SCHEMBL6890425

C[CH]OC(=O)Oc1ccc(C)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 1/20 0.42
USP2 O75604 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTK2B Q14289 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
PRSS1 P07477 1/20 0.39
ACR P10323 1/20 0.39
MAPT P10636 1/20 0.38
BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894569 0.84 CES2 (0.47) LMNAALDH1A1KMT2AGAACYP1A2
SCHEMBL47792 0.83 LMNA (0.70) LMNAALDH1A1KMT2AGAAUSP2
SCHEMBL16445450 0.82 LMNA (0.53) LMNAALDH1A1KMT2AGAAUSP2
SCHEMBL444563 0.82 MAPT (0.44) ALDH1A1KMT2AGAAUSP2MEN1
SCHEMBL6894175 0.80 MEN1 (0.41) LMNAALDH1A1KMT2AMEN1TDP1
SCHEMBL6891207 0.79 MAPT (0.51) LMNAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL6892716 0.79 RAB9A (0.47) LMNAALDH1A1KMT2AMEN1CYP2C19
SCHEMBL1421470 0.78 GAA (0.58) LMNAALDH1A1KMT2AGAAMEN1
SCHEMBL6890525 0.78 LMNA (0.61) LMNAALDH1A1KMT2AGAAMEN1
SCHEMBL1598492 0.77 LMNA (0.61) LMNAALDH1A1KMT2AGAAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 LMNA 2043/4885ALDH1A1 1161/4885KMT2A 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.